The retraction notice speaks for itself. No need to look for flaws.
Retraction Note: BMC Cardiovascular Disorders (2024) 24:710
The Editors have retracted this article. Concerns have been raised regarding significant discrepancies between the research as described in the article and the description in the accompanying clinical trial registry entry with regards to the study dates, number of participants enrolled, and the (combination of) drugs administered to the participants. Additionally, upon submission the authors failed to disclose relevant competing interests.
The authors have contacted the editors to inform them that the incorrect TRN was included in the article, and that the correct TRN is NCT04334512. However, there remain considerable discrepancies between this clinical trial register entry and the research as described in the article.
Additional review also raised concerns regarding the study design as described in the article. The concerns include, but are not limited to:,
• A potential imbalance in baseline characteristics between the two groups that could compromise the validity of the results.
• The article does not compare hospital and ambulatory patients, contrary to one of the stated objectives of this study.
• The study appears to lack both consideration of necessary confounding factors and sufficient statistical power, leading to arguably overstated conclusions regarding the safety and efficacy of HAZDPac.
The Editors therefore no longer have confidence in the results and conclusions as stated in this article as they do not appear to be sufficiently supported by the data due to omissions in the study design.
